WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that it has received a $3 million milestone payment from Kyowa Hakko Kogyo Co., Ltd. (Kyowa), marking the initiation by Kyowa of a Phase 1, dose escalation trial in Japan with ARQ 197, a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase. This payment was made under the terms of an exclusive license agreement signed between the two companies in April 2007.
